The S&P/ASX Small Ordinaries Index (ASX: XSO) traded lower, closing at 3,482.40 points, down 2.02% or 71.90 points on the previous session.
Over the past five days, the small-cap benchmark has fallen 2.08%, or 73.90 points, reflecting weaker sentiment across the smaller end of the Australian equities market.
Positive research from Breakaway Research has highlighted Carnavale Resources Ltd (ASX:CAV, FRA:YBB) as a speculative buy opportunity, with senior analyst Mark Gordon pointing to the company’s high-grade Kookynie Gold Project in Western Australia as a near-term, low-capex gold development story with strong margin potential.
Carnavale owns 80% of Kookynie, which sits 60 kilometres south of Leonora in the Eastern Goldfields, one of Australia’s premier gold mining districts. The company is advancing the project toward a bankable feasibility study (BFS), targeted for completion in Q3 2026, with a strategy based on contract mining and ore sales or toll treatment through existing regional processing infrastructure rather than building a standalone plant.
Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States and started key 2026 field work at its Estelle Gold and Critical Minerals Project in Alaska, including drilling for antimony and gold.
The company’s common stock and listed warrants were now trading on the NYSE American under the ticker symbols NVA and NVAWS, while Chess Depositary Interests continue to trade on the ASX under NVA.
Dalaroo Metals Ltd (ASX:DAL) is mobilising for an expanded 2026 exploration campaign at its Blue Lagoon Critical Minerals Project in southern Greenland, setting up the company for its most comprehensive field program at the project to date.
The campaign will follow up Dalaroo’s maiden 2025 field season, which identified a 2.7-kilometre mineralised corridor with peak results of 4.42% zirconium dioxide, 99ppm hafnium and 0.81% total rare earth oxides.
Australia has signed a landmark $2.5 billion government-to-government agreement with Canada to export Australian Over the Horizon Radar (OTHR) technology, marking the nation’s largest-ever defence export.
The agreement is the first international sale of Australia’s OTHR capability, which has been developed through the Jindalee Operational Radar Network (JORN), one of the country’s most significant sovereign defence technology programs.
G50 Corp Ltd (ASX:G50, OTCQB:GFYTF) has delivered a strong first result from its 2026 core drilling program at the White Caps Gold Project in Nevada, intersecting 13.5 metres at 7.67 g/t gold and 2.38 g/t silver from 305.5 metres.
The result from hole WCD26-01 included a higher-grade interval of 3.93 metres at 23.95 g/t gold and 7.29 g/t silver from the same depth, marking the first reported assay from a 5-hole, 2,220.10-metre program.
Hastings Technology Metals Ltd (ASX:HAS, OTC:HSRMF) has secured a $1 million strategic investment from Malaco Mining Sdn. Bhd., adding balance sheet flexibility as it advances its rare earths strategy across Australia and Thailand.
The investment will be completed through a placement of 2,739,726 fully paid ordinary shares at $0.365 per share, with the shares to be issued under Hastings’ existing placement capacity under ASX Listing Rule 7.1A.
Toubani Resources Ltd (ASX:TRE) has delivered a strong batch of high-grade reverse circulation drilling results from its Kobada Gold Project in southern Mali, supporting resource definition work ahead of an updated mineral resource estimate and planned start of mining activities in early 2027.
The results come from pre-production infill drilling in the northern area of the Kobada mineral resource estimate (MRE), as well as follow-up drilling at Kobada South, where the company is targeting near-surface oxide mineralisation to provide additional mining flexibility.
Conneqt Health Ltd (ASX:CQT) has taken a key step toward expanding its cardiovascular health technology platform, lodging an FDA Pre-Submission package for SphygmoCor Cloud, its next-generation Software as a Medical Device (SaMD) platform.
The company is looking to begin the pathway to 510(k) clearance in the US, with written feedback from the US Food and Drug Administration expected in August 2026.
Vection Technologies Ltd (ASX:VR1) has secured around $2.3 million in new AI-related contracts across five sectors, extending its recent order momentum to about $7 million since the start of April 2026.
The new orders comprise about $990,000 in one-time contracts and a $1.3 million annual recurring revenue contract, with around $2 million to be recognised in FY26 and $300,000 in FY27.